Extract
Blood eosinophil count is a readily available biomarker in chronic obstructive pulmonary disease (COPD) that can assist identification of patients most likely to benefit from inhaled corticosteroids (ICS) [1]. Recent evidence has demonstrated a link between blood eosinophil count as a continuous variable and magnitude of response to ICS in terms of exacerbation rate reduction [2, 3]. The current Global Initiative for Chronic Obstructive Lung Disease (GOLD) report recommends that blood eosinophil count can be used to predict the likelihood of beneficial response to ICS, in combination with clinical assessment of exacerbation risk [1]. However, as blood eosinophil counts can show variability, particularly at higher levels [4–6], it is of clinical interest to determine how many measurements are sufficient to predict an ICS response in patients with COPD. Data from the InforMing the PAthway of COPD Treatment (IMPACT) trial showed an association between blood eosinophil count and ICS response on reduction of moderate/severe COPD exacerbations [3]. This post hoc analysis of IMPACT compared whether one or two measurements of blood eosinophil count can better predict ICS responses in patients with COPD.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Bafadhel reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; grants and other from AstraZeneca, other from Chiesi, other from Boehringer Ingelheim, other from GlaxoSmithKline, other from ProAxsis, other from AlbusHealth, outside the submitted work.
Conflict of interest: Dr. Barnes reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, other from GlaxoSmithKline, outside the submitted work; .
Conflict of interest: Dr. Bourke reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; grants and non-financial support from GlaxoSmithKline, grants from Philips, grants and personal fees from ResMed, grants from Pfizer Open Air, non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Chiesi, personal fees, non-financial support and other from AstraZeneca, personal fees from Novartis, outside the submitted work.
Conflict of interest: Dr. Compton reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, other from GlaxoSmithKline, outside the submitted work; .
Conflict of interest: Dr. Criner reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from Almirall, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from CSA Medical, personal fees from Eolo, personal fees from GlaxoSmithKline, other from HGE Technologies, personal fees from Novartis, personal fees from Nuvaira, personal fees from Olympus, personal fees from Pulmonx, personal fees from Verona, personal fees from Amgen, personal fees from Broncus Medical, personal fees from Gala Therapeutics, personal fees from Helios Medical, personal fees from Medtronic, personal fees from Merck, personal fees from Mereo Biopharma, personal fees from NGM Pharmaceuticals, personal fees from Philips Respironics, personal fees from Respivant Sciences, personal fees from The Implementation Group, outside the submitted work; .
Conflict of interest: Dr. Dransfield reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees and other from Boehringer Ingelheim, personal fees and other from GlaxoSmithKline, personal fees and other from AstraZeneca, personal fees and other from PneumRx/BTG, personal fees from Quark Pharmaceuticals, grants from American Lung Association, grants from Department of Defense, grants from Department of Veterans Affairs, grants from NIH, other from Novartis, other from Yungjin, other from Pulmonx, other from Boston Scientific, other from Gala, other from Nuvaira, outside the submitted work; .
Conflict of interest: Dr. Halpin reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GlaxoSmithKline, personal fees and non-financial support from Novartis, personal fees from Pfizer, personal fees from Sanofi, outside the submitted work; .
Conflict of interest: Dr. Han reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from GlaxoSmithKline, other from Novartis, other from Sunovion, personal fees from Mylan, personal fees from Merck, personal fees from Verona, personal fees from Teva, outside the submitted work; .
Conflict of interest: Dr. Hartley reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees and other from GlaxoSmithKline, outside the submitted work; .
Conflict of interest: Dr. Jones reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, other from GlaxoSmithKline, outside the submitted work; .
Conflict of interest: Dr. Lange reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants and personal fees from GlaxoSmithKline, outside the submitted work; .
Conflict of interest: Dr. Lettis reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, other from GlaxoSmithKline, outside the submitted work; .
Conflict of interest: Dr. Lipson reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, other from GlaxoSmithKline, outside the submitted work; .
Conflict of interest: Dr. Lomas reports personal fees from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; grants, personal fees and other from GlaxoSmithKline, personal fees from Griffols, outside the submitted work; .
Conflict of interest: Dr. Martin reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, other from GlaxoSmithKline, outside the submitted work; .
Conflict of interest: Dr. Martinez reports personal fees, non-financial support and other from AtraZeneca, other from Afferent/Merck, personal fees, non-financial support and other from Boheringer Ingelheim, other from Bristol Myers Squibb, other from Chiesi, personal fees and non-financial support from Canadian Respiratory Society, personal fees and non-financial support from CME Outfitters, personal fees and non-financial support from CSL Behring, personal fees from Dartmouth University, personal fees from France Foundation, personal fees from Gala, personal fees and non-financial support from Genentech, grants, personal fees, non-financial support and other from GlaxoSmithKline, personal fees and non-financial support from Inova Fairfax, personal fees and non-financial support from MDMagazine, personal fees and non-financial support from NYP Methodist Hospital Brooklyn, personal fees and non-financial support from Miller Communications, personal fees and non-financial support from National Association for Continuing Education, other from Nitto, personal fees and non-financial support from Novartis, personal fees from New York University, personal fees and non-financial support from Patara/Respivant, personal fees from Pearl, personal fees and non-financial support from Peer View, personal fees from Physicians Education Resource, personal fees from ProMedior, personal fees and non-financial support from Rare Diseases Healthcare Communications, personal fees from Rockpointe Communications, personal fees and non-financial support from Sanofi/Regeneron, other from Biogen, personal fees and non-financial support from Sunovion, personal fees and non-financial support from Teva, other from twoXR, personal fees from University of Birmingham Alabama, personal fees from UpToDate, non-financial support from Veracyte, personal fees from Vindico, personal fees and non-financial support from WebMD/MedScape, non-financial support and other from Zambon, non-financial support from ProTerrix Bio, personal fees from IQVIA, outside the submitted work; .
Conflict of interest: Dr. Wise reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; grants and personal fees from AstraZeneca / Medimmune , grants and personal fees from Boehringer Ingelheim, personal fees from Contrafect, personal fees from Pulmonx, personal fees from Roche, personal fees from Sunovion, grants from Pearl Therapeutics, personal fees from Merck, personal fees from Circassia, personal fees from Pneuma, personal fees from Verona, personal fees from Mylan/Theravance, personal fees from Propeller Health, grants from Sanofi-Aventis, personal fees from AbbVie, grants and personal fees from GSK, personal fees from Kiniksa, personal fees from Galderma, personal fees from Kinevant, personal fees from Chimerx, personal fees from Puretech, personal fees from Kamada, outside the submitted work; .
Conflict of interest: Dr. Singh reports other from GlaxoSmithKline, non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Chiesi, personal fees from Cipla, personal fees from Genentech, grants and personal fees from Glenmark, grants and personal fees from Menarini, grants and personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Peptinnovate, grants and personal fees from Pfizer, grants and personal fees from Pulmatrix, grants and personal fees from Theravance, grants and personal fees from Verona, outside the submitted work; .
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org